UNASSIGNED: @entity792 , such as @entity1701 , @entity1252 and @entity309 , are characterized by a high prevalence of @entity65 , which constitutes the leading causes of morbidity and mortality among such @entity1 . Although such effects are partly explained by a higher prevalence of traditional CV risk factors, many studies indicate that such factors do not fully explain the enhanced CV risk in these @entity1 . In addition, risk stratification algorithms based upon traditional CV risk factors are not as predictive in @entity792 as in the general population. For these reasons, the timely and accurate assessment of CV risk in these high-risk populations still remains an unmet clinical need. An enhanced contribution of different inflammatory components of the immune response, as well as autoimmune elements (e.g. autoantibodies, autoantigens and cellular response) have been proposed to underlie the incremental CV risk observed in these populations. Recent advances in proteomic tools have contributed to the discovery of proteins involved in @entity65 , including some that may be suitable to be used as biological markers. In this review we summarize the main markers in the field of @entity65 associated with autoimmunity, as well as the recent advances in proteomic technology and their application for biomarker discovery in @entity792 . This article is protected by copyright. All rights reserved.

Biomarkers for cardiovascular risk assessment in XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1252 :: ('MESH:D008180', 'Disease') :: ['systemic lupus erythematosus'] @entity1701 :: ('MESH:D016736', 'Disease') :: ['antiphospholipid syndrome'] @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular (CV) disease', 'CV diseases'] @entity792 :: ('MESH:D001327', 'Disease') :: ['autoimmune disease', 'autoimmune diseases', 'Autoimmune diseases'] @entity309 :: ('MESH:D001172', 'Disease') :: ['rheumatoid arthritis']
@entity792 :: (MESH:D001327,Disease) :: ['autoimmune diseases']
